SEC Declares Mangoceuticals’ Form S-1 Effective on June 18 2025
Rhea-AI Filing Summary
Filing highlight: Mangoceuticals, Inc. (CIK 0001938046; symbol MGRX) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission.
The SEC declared the company’s Form S-1 registration statement (File No. 333-287689) effective at 5:00 p.m. on June 18, 2025. This notice confirms that the registration statement has completed the Commission’s review and is now operative.
No further details—such as the size, terms, or purpose of the registered securities—were disclosed in the notice.
Positive
- SEC declared Mangoceuticals’ Form S-1 registration statement effective on June 18, 2025
Negative
- None.
Insights
TL;DR: SEC green-lights Mangoceuticals’ S-1 on June 18 2025; enables registered securities to be offered, but no deal terms disclosed.
The Notice of Effectiveness signifies regulatory clearance of Mangoceuticals’ Form S-1. While this is a necessary step toward any future capital raise, the filing supplies no information about share count, pricing, or intended use of proceeds. Consequently, the development is procedurally positive yet its material financial impact remains indeterminate until the company releases offering specifics.
FAQ
What SEC action was announced for Mangoceuticals (MGRX)?
When did the Form S-1 for Mangoceuticals become effective?
Which form type is associated with this Mangoceuticals filing?
What is Mangoceuticals’ CIK number in this filing?
Does the notice specify the size or terms of the offering?
